1H-magnetic resonance spectroscopy in obsessive–compulsive disorder: effects of 12 weeks of sertraline treatment on brain metabolites

European Archives of Psychiatry and Clinical Neuroscience

Volumn 265, Issue 3, 2015, Pages 219-226

  Tükel, Raşit ^a   Aydın, Kubilay ^a   Ertekin, Erhan ^a   Özyıldırım, Seda Şahin ^a   Barburoğlu, Mehmet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Magnetic resonance spectroscopy; N acetylaspartate; Neuroimaging; Obsessive compulsive disorder; Sertraline

Indexed keywords

CHOLINE; CREATINE; INOSITOL; N ACETYLASPARTIC ACID; SERTRALINE; ASPARTIC ACID; N-ACETYLASPARTATE; PROTON; SEROTONIN UPTAKE INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADULT; ANTERIOR CINGULATE; ARTICLE; BRAIN METABOLISM; CAUDATE NUCLEUS; CHRONOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MENTAL PATIENT; NEUROCHEMISTRY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOPHARMACOTHERAPY; PUTAMEN; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BRAIN; DRUG EFFECTS; FOLLOW UP; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSESSIVE-COMPULSIVE DISORDER; PATHOLOGY; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; ASPARTIC ACID; BRAIN; CHOLINE; CREATINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OBSESSIVE-COMPULSIVE DISORDER; PROTONS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; YOUNG ADULT;

EID: 84925535045     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-014-0545-1     Document Type: Article

References (42)

1. Baxter LR Jr, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE (1987) Local cerebral glucose metabolic rates in obsessive–compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 44:211–218
2. Nordahl TE, Benkelfat C, Semple WE, Gross M, King AC, Cohen RM (1989) Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology 2:23–28
3. Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A et al (1989) Cerebral glucose metabolism in childhood-onset obsessive–compulsive disorder. Arch Gen Psychiatry 46:518–523
4. Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HC, Savage CR, Fischman AJ (1994) Regional cerebral blood flow measured during symptom provocation in obsessive–compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 51:62–70
5. Breiter HC, Rauch SL, Kwong KK, Baker JR, Weisskoff RM, Kennedy DN et al (1996) Functional magnetic resonance imaging of symptom provocation in obsessive–compulsive disorder. Arch Gen Psychiatry 53:595–606
6. Adler CM, McDonough-Ryan P, Sax KW, Holland SK, Arndt S, Strakowski SM (2000) fMRI of neuronal activation with symptom provocation in unmedicated patients with obsessive compulsive disorder. J Psychiatr Res 34:317–324
7. Trzesniak C, Araujo D, Crippa JAS (2008) Magnetic resonance spectroscopy in anxiety disorders. Acta Neuropsychiatr 20:56–71
8. Brennan BP, Rauch SL, Jensen JE, Pope HG Jr (2013) A critical review of magnetic resonance spectroscopy studies of obsessive–compulsive disorder. Biol Psychiatry 73:24–31
9. Tsai G, Coyle JT (1995) N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 46:531–540
10. Ebert D, Speck O, König A, Berger M, Hennig J, Hohagen F (1997) 1H-magnetic resonance spectroscopy in obsessive–compulsive disorder: evidence for neuronal loss in the cingulate gyrus and the right striatum. Psychiatry Res 74:173–176
11. Baslow MH (2010) Evidence that the tri-cellular metabolism of N-acetylaspartate functions as the brain’s “operating system”: how NAA metabolism supports meaningful intercellular frequency-encoded communications. Amino Acids 39:1139–1145
12. Jang JH, Kwon JS, Jang DP, Moon WJ, Lee JM, Ha TH et al (2006) A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive–compulsive disorder. Am J Psychiatry 163:1202–1207
13. Sumitani S, Harada M, Kubo H, Ohmori T (2007) Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive–compulsive disorder patients. Psychiatry Res 154:85–92
14. Yücel M, Harrison BJ, Wood SJ, Fornito A, Wellard RM, Pujol J (2007) Functional and biochemical alterations of the medial frontal cortex in obsessive–compulsive disorder. Arch Gen Psychiatry 64:946–955
15. Whiteside SP, Abramowitz JS, Port JD (2012) The effect of behavior therapy on caudate N-acetyl-l-aspartic acid in adults with obsessive–compulsive disorder. Psychiatry Res 201:10–16
16. Bartha R, Stein MB, Williamson PC, Drost DJ, Neufeld RW, Carr TJ et al (1998) A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive–compulsive disorder and comparison subjects. Am J Psychiatry 155:1584–1591
17. Mohamed MA, Smith MA, Schlund MW, Nestadt G, Barker PB, Hoehn-Saric R (2007) Proton magnetic resonance spectroscopy in obsessive–compulsive disorder: a pilot investigation comparing treatment responders and non-responders. Psychiatry Res 156:175–179
18. Fitzgerald KD, Moore GJ, Paulson LA, Stewart CM, Rosenberg DR (2000) Proton spectroscopic imaging of the thalamus in treatment-naive pediatric obsessive–compulsive disorder. Biol Psychiatry 47:174–182
19. Ohara K, Isoda H, Suzuki Y, Takehara Y, Ochiai M, Takeda H et al (1999) Proton magnetic resonance spectroscopy of lenticular nuclei in obsessive–compulsive disorder. Psychiatry Res 92:83–91
20. Fan Q, Tan L, You C, Wang J, Ross CA, Wang X et al (2010) Increased N-acetylaspartate/creatine ratio in the medial prefrontal cortex among unmedicated obsessive–compulsive disorder patients. Psychiatry Clin Neurosci 64:483–490
21. Aoki Y, Aoki A, Suwa H (2012) Reduction of N-acetylaspartate in the medial prefrontal cortex correlated with symptom severity in obsessive–compulsive disorder: meta-analyses of (1)H-MRS studies. Transl Psychiatry 2:e153. doi:10.1038/tp.2012.78
22. Whiteside SP, Port JD, Deacon BJ, Abramowitz JS (2006) A magnetic resonance spectroscopy investigation of obsessive–compulsive disorder and anxiety. Psychiatry Res 146:137–147
23. Lázaro L, Bargalló N, Andrés S, Falcón C, Morer A, Junqué C, Castro-Fornieles J (2012) Proton magnetic resonance spectroscopy in pediatric obsessive–compulsive disorder: longitudinal study before and after treatment. Psychiatry Res 201:17–24
24. Yücel M, Wood SJ, Wellard RM, Harrison BJ, Fornito A, Pujol J et al (2008) Anterior cingulate glutamate–glutamine levels predict symptom severity in women with obsessive–compulsive disorder. Aust N Z J Psychiatry 42:467–477
25. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (DSM-IV), 4th ed. American Psychiatric Press, Washington
26. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured Clinical Interview for DSM-IV Clinical Version (SCID-I/CV). American Psychiatric Press, Washington
27. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL et al (1989) The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006–1011
28. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS (1989) The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46:1012–1016
29. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55
30. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296
31. Baslow MH (2002) Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Neurochem Int 40:295–300
32. Baslow MH (2003) N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res 28:941–953
33. Barker PB (2001) N-acetyl aspartate—a neuronal marker? Ann Neurol 49:423–424
34. Maddock RJ, Buonocore MH (2012) MR spectroscopic studies of the brain in psychiatric disorders. In: Carter CS, Dalley JW (eds) Brain imaging in behavioral neuroscience. Springer, Berlin, pp 199–251
35. Baxter LR Jr, Schwartz JM, Mazziotta JC, Phelps ME, Pahl JJ, Guze BH, Fairbanks L (1988) Cerebral glucose metabolic rates in nondepressed patients with obsessive–compulsive disorder. Am J Psychiatry 145:1560–1563
36. Hollander E, Prohovnik I, Stein DJ (1995) Increased cerebral blood flow during m-CPP exacerbation of obsessive–compulsive disorder. J Neuropsychiatry Clin Neurosci 7:485–490
37. Baxter LR Jr, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC et al (1992) Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive–compulsive disorder. Arch Gen Psychiatry 49:681–689
38. Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL et al (1992) Cerebral glucose metabolism in childhood-onset obsessive–compulsive disorder. Revisualization during pharmacotherapy. Arch Gen Psychiatry 49:690–694
39. Perani D, Colombo C, Bressi S, Bonfanti A, Grassi F, Scarone S et al (1995) [18F]FDG PET study in obsessive–compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry 166:244–250
40. Rotge JY, Guehl D, Dilharreguy B, Cuny E, Tignol J, Bioulac B et al (2008) Provocation of obsessive–compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci 33:405–412
41. Del Casale A, Kotzalidis GD, Rapinesi C, Serata D, Ambrosi E, Simonetti A et al (2011) Functional neuroimaging in obsessive–compulsive disorder. Neuropsychobiology 64:61–85
42. Benazon NR, Moore GJ, Rosenberg DR (2003) Neurochemical analyses in pediatric obsessive–compulsive disorder in patients treated with cognitive-behavioral therapy. J Am Acad Child Adolesc Psychiatry 42:1279–1285